Integral Investment Advisors Inc. Grows Stock Holdings in Pfizer Inc. (NYSE:PFE)

Integral Investment Advisors Inc. increased its stake in Pfizer Inc. (NYSE:PFE) by 4.5% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 55,525 shares of the biopharmaceutical company’s stock after buying an additional 2,385 shares during the period. Integral Investment Advisors Inc.’s holdings in Pfizer were worth $1,473,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Wealthspire Advisors LLC boosted its stake in Pfizer by 1.7% in the 4th quarter. Wealthspire Advisors LLC now owns 125,762 shares of the biopharmaceutical company’s stock worth $3,336,000 after purchasing an additional 2,136 shares in the last quarter. TCW Group Inc. boosted its stake in Pfizer by 2.5% during the 4th quarter. TCW Group Inc. now owns 79,538 shares of the biopharmaceutical company’s stock valued at $2,110,000 after purchasing an additional 1,971 shares during the last quarter. Denver PWM LLC increased its holdings in shares of Pfizer by 14.5% in the 4th quarter. Denver PWM LLC now owns 3,426 shares of the biopharmaceutical company’s stock worth $91,000 after purchasing an additional 435 shares in the last quarter. Fisher Funds Management LTD purchased a new position in shares of Pfizer in the fourth quarter worth $11,804,000. Finally, Lipe & Dalton lifted its holdings in shares of Pfizer by 17.7% during the fourth quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 400 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on PFE. Guggenheim reiterated a “buy” rating and issued a $33.00 price objective on shares of Pfizer in a report on Monday, February 10th. Bank of America reissued a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. Citigroup dropped their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. UBS Group decreased their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Finally, Truist Financial dropped their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Insider Buying and Selling

In related news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction dated Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.06% of the stock is owned by insiders.

Pfizer Price Performance

NYSE PFE opened at $26.32 on Friday. The stock has a market cap of $149.14 billion, a price-to-earnings ratio of 18.66, a PEG ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The company’s 50 day moving average is $26.30 and its two-hundred day moving average is $27.41. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter in the previous year, the company earned $0.10 EPS. Pfizer’s revenue for the quarter was up 24.7% on a year-over-year basis. As a group, research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.54%. The ex-dividend date is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is 121.99%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.